Avadel Pharmaceuticals PLC

Healthcare US AVDL

9.43USD
0.09(0.96%)

Last update at 2025-06-13T16:45:00Z

Day Range

9.179.52
LowHigh

52 Week Range

9.5019.09
LowHigh

Fundamentals

  • Previous Close 9.34
  • Market Cap1504.93M
  • Volume403973
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-133.86700M
  • Revenue TTM55.14M
  • Revenue Per Share TTM0.63
  • Gross Profit TTM 16.59M
  • Diluted EPS TTM-1.82

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -111.43900M -93.14500M -5.08200M -38.58200M -113.19700M
Minority interest - - - - -
Net income -137.46400M -77.32900M 7.03M -33.22600M -95.30400M
Selling general administrative 74.52M 68.50M 32.41M 30.18M 100.36M
Selling and marketing expenses - - - - -
Gross profit - 0.00000M 16.59M 47.09M 85.75M
Reconciled depreciation 1.49M 0.81M 1.69M 2.49M 7.43M
Ebit -98.56100M -85.54600M -36.66100M -16.82600M -60.55400M
Ebitda -93.72300M -84.56700M -31.60700M -14.34000M -53.12400M
Depreciation and amortization 4.84M 0.98M 5.05M 2.49M 7.43M
Non operating income net other - 2.13M -1.26700M -1.98700M 2.35M
Operating income -98.56100M -85.54600M -36.66100M -16.82600M -104.92600M
Other operating expenses 95.22M 85.60M 58.99M 76.04M 163.82M
Interest expense 12.34M 9.94M 12.99M 12.48M 10.62M
Tax provision 26.02M -15.81600M -12.11000M -5.35600M -17.89300M
Interest income - - - 12.48M 10.62M
Net interest income -12.34200M -9.94200M -12.99400M -12.48300M -10.62200M
Extraordinary items - - - - 0.27M
Non recurring - - 3.33M 0.84M 43.36M
Other items - - - - -
Income tax expense 26.02M -15.81600M -12.11000M -5.35600M -17.89300M
Total revenue 0.00000M 0.00000M 22.33M 59.22M 103.27M
Total operating expenses 95.22M 85.60M 53.25M 63.92M 146.31M
Cost of revenue - 0.00000M 5.74M 12.12M 17.52M
Total other income expense net -12.87800M -7.59900M 31.58M -21.75600M -42.02100M
Discontinued operations - - - - -
Net income from continuing ops -137.46400M -77.32900M 7.03M -33.22600M -95.30400M
Net income applicable to common shares -137.46400M -77.32900M 7.03M -33.22600M -95.30400M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 261.13M 132.78M 247.26M 311.64M 151.44M
Intangible assets - - - - 0.81M
Earning assets - - - - -
Other current assets 5.29M 2.10M 32.83M 38.73M 4.26M
Total liab 173.39M 153.93M 169.02M 149.37M 180.63M
Total stockholder equity 87.74M -21.14500M 78.24M 162.27M -29.19900M
Deferred long term liab - - - - -
Other current liab 24.49M 9.28M 5.27M 5.20M 3.88M
Common stock 0.90M 0.63M 0.59M 0.58M 0.43M
Capital stock 0.95M 0.63M 0.59M 0.59M 0.43M
Retained earnings -745.49600M -585.22000M -447.75600M -384.18700M -391.21500M
Other liab - 5.74M 3.92M 4.21M 20.65M
Good will 16.84M 16.84M 16.84M 16.84M 18.49M
Other assets - 12.55M 35.00M 28.38M 39.17M
Cash 31.17M 73.98M 50.71M 71.72M 9.77M
Cash and equivalents - - - - -
Total current liabilities 36.85M 55.79M 21.00M 15.11M 35.98M
Current deferred revenue - - 7.15M 6.50M 25.36M
Net debt 4.22M 57.04M 94.30M 58.80M 114.88M
Short term debt 0.93M 38.63M 0.90M 0.47M 0.65M
Short long term debt - 37.67M - - -
Short long term debt total 35.38M 131.02M 145.00M 130.52M 124.65M
Other stockholder equity 855.45M 589.78M 549.35M 566.92M 384.39M
Property plant equipment - 2.55M 0.28M 0.36M 0.54M
Total current assets 134.20M 100.84M 192.49M 263.45M 82.38M
Long term investments - - - - -
Net tangible assets - -37.98600M 61.40M 145.43M -48.50300M
Short term investments 73.94M 22.52M 106.51M 149.68M 54.38M
Net receivables 13.43M 2.25M 2.44M 3.33M 10.39M
Long term debt - 91.61M 142.40M 128.21M 121.69M
Inventory 10.38M - - 0.00000M 3.57M
Accounts payable 11.43M 7.89M 7.68M 2.93M 6.10M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -23.16700M -26.34100M -23.94000M -21.05100M -22.80600M
Additional paid in capital - - - - -
Common stock total equity - - 0.59M 0.58M 0.43M
Preferred stock total equity - - 0.00500M 0.00500M -
Retained earnings total equity - - -447.75600M -384.18700M -391.21500M
Treasury stock - - - - -49.99800M
Accumulated amortization - - - - -
Non currrent assets other 10.15M 12.55M 33.78M 24.94M 39.27M
Deferred long term asset charges - - - - -
Non current assets total 126.92M 31.94M 54.77M 48.18M 69.06M
Capital lease obligations 2.62M 1.74M 2.61M 2.31M 2.96M
Long term debt total - - 142.40M 128.21M 121.69M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 79.70M 40.45M -95.12300M 38.60M -16.80300M
Change to liabilities -3.10800M 5.13M -16.01400M 4.97M -13.01300M
Total cashflows from investing activities 79.70M 56.93M -69.72100M 38.72M -36.98100M
Net borrowings -8.65300M -8.65300M -8.65300M -8.65300M 137.56M
Total cash from financing activities 14.54M 0.26M 179.68M -0.02700M 112.66M
Change to operating activities 27.64M -0.53700M -18.46500M -18.60700M -33.91500M
Net income -137.46400M -77.32900M 7.03M -33.22600M -95.30400M
Change in cash 23.27M -21.01400M 61.95M 0.45M -7.23900M
Begin period cash flow 50.71M 71.72M 9.77M 9.32M 16.56M
End period cash flow 73.98M 50.71M 71.72M 9.77M 9.32M
Total cash from operating activities -70.30400M -77.31000M -48.73400M -38.32500M -82.71600M
Issuance of capital stock 25.32M 0.26M 179.68M 0.12M 0.58M
Depreciation 1.49M 0.81M 1.69M 2.49M 7.43M
Other cashflows from investing activities - 16.50M 25.50M 0.15M -20.00000M
Dividends paid - - - - -
Change to inventory - 0.00000M -1.35200M 1.16M 0.71M
Change to account receivables - 0.00000M 8.28M 2.47M 3.45M
Sale purchase of stock - 0.26M 179.68M 0.12M -27.63700M
Other cashflows from financing activities -2.12200M 56.93M -69.72100M -0.14500M 139.72M
Change to netincome 35.08M -5.52200M -50.05000M -6.06900M 58.98M
Capital expenditures 0.72M 0.03M 0.10M 0.03M 20.18M
Change receivables - - 8.28M 2.47M 3.45M
Cash flows other operating - -1.64900M -4.84100M -16.10500M -49.79700M
Exchange rate changes - - - - -0.20100M
Cash and cash equivalents changes - -20.11800M 61.23M 0.37M -7.23900M
Change in working capital 24.54M 3.69M -8.13500M 2.25M -11.71100M
Stock based compensation 7.01M 8.87M 3.00M 0.52M 7.85M
Other non cash items 8.09M 2.30M -44.88500M -4.02200M 28.17M
Free cash flow -71.02000M -77.33600M -48.83200M -38.35400M -102.89400M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AVDL
Avadel Pharmaceuticals PLC
0.09 0.96% 9.43 - - 51.79 16.52 48.13 -9.0253
ZTS
Zoetis Inc
-3.2725 1.94% 165.55 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR
-0.3 1.12% 26.54 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
4.73 3.60% 136.25 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR
-0.12 0.78% 15.27 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Avadel Pharmaceuticals PLC

10 Earlsfort Terrace, Dublin, Ireland, 2

Key Executives

Name Title Year Born
Mr. Gregory J. Divis Jr. CEO & Director 1967
Mr. Thomas S. McHugh Sr. VP & CFO 1965
Mr. Richard Kim Chief Commercial Officer 1969
Mr. Jerad G. Seurer Gen. Counsel & Company Sec. NA
Mr. Gregory J. Davis VP of Corp. and Bus. Devel. 1965
Mr. Mark W. Elrod VP of Sales NA
Ms. Angie Woods VP of People & Culture NA
Mr. Christian Kalita Pharm.D Chief Pharmacist and Director of Quality Assurance & Regulatory Affairs NA
Mr. Steven G. Sullivan VP of Sales & Marketing and Head of Commercial Operations 1965
Dr. Jordan S. Dubow M.D. Consultant 1978

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.